ReviewInternational journal of nanomedicine2026
Recent Advances in Glimepiride Solubility Improvement: A Focus on Formulation Technologies - A Narrative Review.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glimepiride, a second-generation sulfonylurea used in the management of type 2 diabetes mellitus, is classified as a Biopharmaceutics Classification System (BCS) Class II drug. Its severely limited aqueous solubility (<0.004 mg/mL at pH <7) leads to erratic and insufficient oral bioavailability, preventing consistent attainment of therapeutic plasma levels. This narrative review analyzes literature published between 2015 and 2025 from databases including PubMed, Scopus, and ScienceDirect. This review critically examines advanced formulation strategies designed to enhance Glimepiride's dissolution rate and aqueous solubility. Approaches are grouped into two categories: (1) solid-state modifications-including solid dispersions, co-crystals, and inclusion complexes-which alter the drug's solid state properties, with co-crystals reported to improve in vivo absorption by up to 2.66-fold; and (2) nanoparticle-based systems such as nanosuspensions and self-nanoemulsifying drug delivery systems (SNEDDS), which increase surface area through particle size reduction, with nanosuspensions achieving up to a 6.58-fold solubility enhancement. The advantages and limitations of these technologies are evaluated to identify the most promising strategies for improving glimepiride's therapeutic performance and supporting better patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.